Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CAO Sells $437,316.25 in Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) CAO Michael R. Megna sold 15,211 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $28.75, for a total transaction of $437,316.25. Following the transaction, the chief accounting officer now directly owns 32,546 shares of the company's stock, valued at approximately $935,697.50. This trade represents a 31.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA traded up $0.71 during mid-day trading on Friday, hitting $30.23. 1,070,343 shares of the company's stock were exchanged, compared to its average volume of 505,355. The stock's 50-day moving average is $24.27 and its 200-day moving average is $21.91. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -215.91 and a beta of 0.06. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $30.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm's revenue was up 72.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.25) earnings per share. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on KNSA shares. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price target on the stock. Wall Street Zen cut shares of Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday. Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, April 16th. Finally, Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

Institutional Trading of Kiniksa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Braidwell LP raised its holdings in Kiniksa Pharmaceuticals by 19.3% in the fourth quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after acquiring an additional 557,934 shares in the last quarter. Vanguard Group Inc. raised its holdings in Kiniksa Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company's stock valued at $74,606,000 after acquiring an additional 151,604 shares in the last quarter. Acadian Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals by 170.3% in the first quarter. Acadian Asset Management LLC now owns 1,034,321 shares of the company's stock valued at $22,961,000 after acquiring an additional 651,700 shares in the last quarter. Millennium Management LLC raised its holdings in Kiniksa Pharmaceuticals by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after acquiring an additional 67,452 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in Kiniksa Pharmaceuticals by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock valued at $15,737,000 after acquiring an additional 54,361 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.